Using more than one substance does not make treatment impossible.

Polysubstance abuse is dependence on two or more substances used simultaneously, in sequence, or in combination. Clinically, it presents in three patterns: simultaneous use, where two substances are taken together (alcohol and benzodiazepines is the most common example); sequential use, where a person rotates between substances to manage withdrawal from one while using another; and unknown combinations, where street drugs contain adulterants the person was not aware of. All three patterns create different clinical challenges, but all three can be managed safely under on-site medical supervision.

Research on co-occurring substance use disorders shows that multiple addictions are far more common than single-substance presentations. SAMHSA TIP 42 on co-occurring disorders confirms that integrated treatment, addressing all substances together rather than isolating one, produces significantly better long-term outcomes than sequential single-substance approaches. Arriving at assessment with more than one substance in your history is not an unusual case. It describes the majority of people who come through the door at Jintara.

The clinical question is not whether treatment is possible. It is how to sequence it safely.

The core clinical problem with polysubstance withdrawal is that different substances carry different risks and peak at different times. Alcohol and benzodiazepines both depress the central nervous system, both reduce the seizure threshold, and both carry risk during withdrawal, but their timelines differ. Alcohol withdrawal peaks between 24 and 48 hours, per the NIAAA alcohol withdrawal review. Benzodiazepine withdrawal peaks later, at days two to five for short-acting benzos. For long-acting benzodiazepines such as diazepam, the seizure risk window is delayed further, running from days three to eight post-last dose. Managing both without clinical oversight significantly increases the danger of seizure at either peak.

Opioid withdrawal, by contrast, is not typically life-threatening, though it is acutely uncomfortable. Stimulant withdrawal presents primarily as psychological depression, fatigue and anhedonia rather than physical danger. The medical team must therefore triage from the outset: which substance poses the greatest physical risk if left unmanaged, and which can be addressed concurrently or in a second phase once the acute picture is clearer.

Understanding the specific alcohol and benzodiazepine interaction is one reason the medical team at Jintara spends significant time in the admissions interview establishing the full substance history rather than relying on the presenting complaint alone.

Not all polysubstance combinations carry the same level of medical risk. CNS depressant combinations represent the highest-risk category. Alcohol with benzodiazepines, opioids with benzodiazepines, and alcohol with opioids all suppress respiratory drive, lower blood pressure, and compound each other's overdose risk. CDC overdose prevention data consistently lists CNS depressant combinations among the leading causes of fatal drug overdose.

Stimulant and depressant combinations present a different kind of danger. The physiology of mixing stimulants and depressants creates a masking effect where the stimulant suppresses the perceived impact of the depressant, making overdose harder to recognise and easier to miscalculate in real time. A person may feel functional and alert at drug levels that are clinically dangerous.

Unknown combinations add a further variable: where street drugs contain fentanyl or benzodiazepines not declared on any label, withdrawal may involve substances the person and the clinical team are not initially aware of. This is why the assessment at Jintara covers not just stated use, but clinical observation in the first 24 hours. Honest disclosure about opioid addiction or polysubstance use at intake is what makes accurate protocol design possible.

When a person with polysubstance use checks in, the first clinical priority is assessment, not detox medication. The psychiatrist meets every client on day one to map the full substance picture: what was used, how much, for how long, and when the last use occurred. The CIWA-Ar (Clinical Institute Withdrawal Assessment for Alcohol, Revised) measures alcohol withdrawal severity and the COWS (Clinical Opiate Withdrawal Scale) covers opioid presentations. Benzodiazepine withdrawal is guided by clinical observation, vital signs monitoring, and nursing assessment.

From this picture, the medical team sequences the protocol. The most physically dangerous withdrawal is addressed first. Where two substances carry overlapping risk, the clinical approach may use one as part of the initial management of the other. Benzodiazepines are sometimes used as part of the alcohol detox protocol, for example, with the benzo taper then following once the acute alcohol risk has resolved. Daily nursing observation and regular psychiatrist review run throughout.

Reading what happens in your first week at Jintara gives a fuller picture of the intake and assessment sequence.

Per SAMHSA TIP 45 on detoxification, the acute phase of a polysubstance detox typically runs 10 to 14 days, compared with seven to ten days for alcohol alone or seven days for most opioid presentations. The extended timeline reflects the sequential structure of the protocol: once the most dangerous withdrawal is medically stabilised, the next substance is addressed. This is not a delay. It is the architecture of safety.

During this phase, clients receive daily nursing observations, regular vital sign checks, and ongoing psychiatrist review. Medication protocols are adjusted as each substance clears. The full 30-day program at Jintara is structured so that this acute phase, however long it takes, completes before the intensive therapeutic work reaches full intensity. Shortening the alcohol detox and medical supervision phase to meet an arbitrary schedule increases medical risk and makes the therapeutic work less effective.

The clinical team explains the timeline clearly at the assessment interview. Clients and their families know what to expect before the process begins.

Waiting for detox to finish before starting any therapeutic work is the older model of addiction treatment. At Jintara, the psychiatrist is involved from day one and the primary therapist, Denise O'Leary, sees most clients from day two. This concurrent model matters particularly in polysubstance cases because the underlying drivers are often more complex. Multiple addictions rarely develop without psychological underpinning, and those patterns begin to surface during the detox phase even before full therapeutic work begins.

The early therapeutic priority is not deep processing. It is stabilisation: helping the client understand what is happening in their body and mind, psychoeducation about the withdrawal process, and the beginning of a working relationship with the clinical team. Lertkhwan Sukpia, Jintara's Head Nurse, describes the first-week priority as getting the physical withdrawal under control first, because "if they have severe physical withdrawal, they cannot do another activity to recover the mental issue." EMDR and deeper trauma processing is introduced once the client is neurologically stable enough for it to be effective.

The treatment program at Jintara is designed so that medical care and therapeutic work run in parallel, with both adjusted to the client's current state rather than a fixed schedule.

Single-substance relapse prevention is built around one set of triggers, one craving pattern, and one high-risk scenario. For a person recovering from multiple substances, that picture is more complex. Stimulant cravings and depressant cravings follow different neurological pathways, are triggered by different contexts, and respond to different coping strategies. A relapse prevention plan that addresses only one substance leaves the others unmanaged.

At Jintara, the written relapse prevention plan is built from the client's specific substance history. It maps the trigger pattern for each substance, addresses likely cross-triggers where avoiding one substance may redirect craving toward another, and provides practical strategies for the environments and relationships the client will return to. Skills-based relapse prevention tools are used in preference to the 12-step model because the approach maps onto the multiple-craving reality of polysubstance recovery more directly.

A completed relapse prevention plan is produced before discharge. Post-discharge peer support options are available for continued structure in early recovery.